C
EWTX icon

Covestor’s Edgewise Therapeutics EWTX Stock Holding History

Covestor’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
8
– – ﹤0.01% 2407
2025
Q4 		$0 Hold
8
– – ﹤0.01% 2393
2025
Q3 		$0 Hold
8
– – ﹤0.01% 2422
2025
Q2 		$0 Buy
8
+3
+60% +$43 ﹤0.01% 2360
2025
Q1 		$0 Hold
5
– – ﹤0.01% 2373
2024
Q4 		$0 Sell
5
-2
-29% -$64 ﹤0.01% 2382
2024
Q3 		$0 Hold
7
– – ﹤0.01% 2368
2024
Q2 		$0 Hold
7
– – ﹤0.01% 2382
2024
Q1 		$0 Buy
+7
New +$111 ﹤0.01% 2379

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Covestor's EWTX Position: Q1 2026 in Review

Covestor held its Edgewise Therapeutics (EWTX) position steady in Q1 2026 at 8 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2407.

Covestor first reported a position in EWTX in Q1 2024 and has held it in 9 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Covestor held 8 shares of Edgewise Therapeutics worth $0 as of Q1 2026.
  • Covestor left its Edgewise Therapeutics share count unchanged in Q1 2026.
  • Edgewise Therapeutics made up ﹤0.01% of Covestor's portfolio in Q1 2026, its #2407 holding.
  • Covestor first reported a position in Edgewise Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Covestor's 13F filing for Q1 2026, filed 5 May 2026.